Reset filter
Palavras-chave
ALL ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

113 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Eligibility DRKS00003796 NCT01209286 B-ALL - Eligibility

- 27/09/2021 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01209286

Eligibility DRKS00005163 NCT01207388 B-ALL - Eligibility

- 27/09/2021 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01207388

Eligibility Leukemia, Lymphocytic NCT00313079

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 35 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00313079

Anamnese und klinische Untersuchung OPAL-Studie DRKS00004421 NCT01619124 ALL - Anamnese und klinische Untersuchung OPAL-Studie

- 20/09/2021 - 1 Formulário, 13 Grupos de itens, 72 Elementos de dados, 2 Idiomas
Grupos de itens: Allgemeine Angaben, Tägliche Aktivitäten, Gehen, Gelenkinspektion, Bewegungsumfang (in °) Hüftgelenk, Bewegungsumfang (in °) Kniegelenk, Bewegungsumfang (in °) Sprunggelenk, Muskelbefund Oberschenkel, Muskelbefund Unterschenkel, Therapiekomplikationen, Begleitmedikation, Spez. Intervention gegen Osteonekrosen, Bemerkungen
Osteonekrosen bei pädiatrischen Patienten mit ALL

On-Study - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients - 2019397v3.0 - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 34 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, ALL: Form Administration, ALL: Disease Description, Comments
Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B24E435-7CDC-500C-E044-0003BA3F9857

On-Study - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment - 2019356v3.0 - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 37 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, ALL: Form Administration, ALL: Disease Description, Comments
Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B24EE5B-237E-50D5-E044-0003BA3F9857

Eligibility NCT01195480 Acute Lymphoblastic Leukemia - Eligibility

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 28 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01195480

Eligibility Acute Lymphoblastic Leukemia NCT01685411

- 17/09/2021 - 1 Formulário, 2 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Busulfan and Cyclophosphamide Followed By ALLO BMT; ODM derived from: https://clinicaltrials.gov/show/NCT01685411

Eligibility Acute Lymphoblastic Leukemia NCT00957320

- 17/09/2021 - 1 Formulário, 2 Grupos de itens, 16 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00957320

Eligibility Acute Lymphoblastic Leukemia NCT02186860

- 17/09/2021 - 1 Formulário, 2 Grupos de itens, 20 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02186860

Eligibility Leukemia NCT00452439

- 02/09/2021 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
A Study of Actonel for the Prevention of Bone Loss; ODM derived from: https://clinicaltrials.gov/show/NCT00452439

Registry Formular AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Registry Formular AIEOP-BFM ALL 2009 NCT01117441

- 15/03/2021 - 1 Formulário, 6 Grupos de itens, 31 Elementos de dados, 1 Idioma
Grupos de itens: Patient Information, Eligibility Criteria, Steroid therapy and chemotherapy regimen, Concomitant studies and storage of clinical samples, Laboratory Diagnostic, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Registry Formular (Please send this to study centre until Day 8) Clinical Trial Number: NCT01117441.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial